Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
8778 | 1218 | 43.8 | 91% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
21 | 4 | UROLOGY & NEPHROLOGY//UROL//JOURNAL OF UROLOGY | 229838 |
272 | 3 | PROSTATE CANCER//PROSTATIC NEOPLASMS//UROL | 43768 |
74 | 2 | PROSTATE CANCER//PROSTATIC NEOPLASMS//RADICAL PROSTATECTOMY | 27992 |
8778 | 1 | PCA3//TMPRSS2 ERG//PROSTATE CANCER ANTIGEN 3 | 1218 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | PCA3 | authKW | 1661326 | 7% | 82% | 81 |
2 | TMPRSS2 ERG | authKW | 1219760 | 5% | 78% | 62 |
3 | PROSTATE CANCER ANTIGEN 3 | authKW | 605221 | 2% | 93% | 26 |
4 | ERG | authKW | 570527 | 9% | 20% | 112 |
5 | TMPRSS2 | authKW | 523693 | 3% | 67% | 31 |
6 | TMPRSS2 ERG FUSION | authKW | 381301 | 1% | 89% | 17 |
7 | SECT TRANSLAT PROSTATE CANC | address | 370798 | 2% | 53% | 28 |
8 | MICHIGAN TRANSLAT PATHOL | address | 366305 | 5% | 24% | 62 |
9 | ERG REARRANGEMENT | authKW | 325890 | 1% | 100% | 13 |
10 | PROSTATE CANCER GENE 3 | authKW | 302610 | 1% | 93% | 13 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Urology & Nephrology | 13260 | 31% | 0% | 373 |
2 | Oncology | 8580 | 44% | 0% | 532 |
3 | Pathology | 2475 | 13% | 0% | 161 |
4 | Cell Biology | 292 | 10% | 0% | 120 |
5 | Andrology | 271 | 1% | 0% | 12 |
6 | Endocrinology & Metabolism | 258 | 7% | 0% | 83 |
7 | Medical Laboratory Technology | 217 | 2% | 0% | 30 |
8 | Genetics & Heredity | 194 | 7% | 0% | 81 |
9 | Medicine, Research & Experimental | 87 | 4% | 0% | 53 |
10 | Biochemistry & Molecular Biology | 12 | 8% | 0% | 95 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | SECT TRANSLAT PROSTATE CANC | 370798 | 2% | 53% | 28 |
2 | MICHIGAN TRANSLAT PATHOL | 366305 | 5% | 24% | 62 |
3 | PROSTATE CANC | 193781 | 5% | 12% | 62 |
4 | GEN VISCERAL THORAC SURG CLIN | 175465 | 1% | 50% | 14 |
5 | MARTINI CLIN | 141006 | 4% | 13% | 44 |
6 | MARTINI CLIN PROSTATE CANC | 136522 | 1% | 34% | 16 |
7 | UROL | 94065 | 53% | 1% | 640 |
8 | GRP CANC EPIGENET | 75205 | 0% | 100% | 3 |
9 | PROSTATE DIS | 72206 | 2% | 10% | 28 |
10 | ADDARII | 60157 | 0% | 40% | 6 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | PROSTATE | 27775 | 6% | 2% | 71 |
2 | MODERN PATHOLOGY | 8338 | 3% | 1% | 40 |
3 | EUROPEAN UROLOGY | 8303 | 4% | 1% | 49 |
4 | PROSTATE CANCER AND PROSTATIC DISEASES | 7506 | 1% | 2% | 18 |
5 | ACTAS UROLOGICAS ESPANOLAS | 4986 | 1% | 1% | 14 |
6 | CURRENT OPINION IN UROLOGY | 3750 | 1% | 1% | 13 |
7 | BJU INTERNATIONAL | 3731 | 3% | 0% | 35 |
8 | NATURE REVIEWS UROLOGY | 3606 | 1% | 2% | 8 |
9 | NEOPLASIA | 3324 | 1% | 1% | 15 |
10 | CLINICAL CANCER RESEARCH | 2386 | 3% | 0% | 38 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | PCA3 | 1661326 | 7% | 82% | 81 | Search PCA3 | Search PCA3 |
2 | TMPRSS2 ERG | 1219760 | 5% | 78% | 62 | Search TMPRSS2+ERG | Search TMPRSS2+ERG |
3 | PROSTATE CANCER ANTIGEN 3 | 605221 | 2% | 93% | 26 | Search PROSTATE+CANCER+ANTIGEN+3 | Search PROSTATE+CANCER+ANTIGEN+3 |
4 | ERG | 570527 | 9% | 20% | 112 | Search ERG | Search ERG |
5 | TMPRSS2 | 523693 | 3% | 67% | 31 | Search TMPRSS2 | Search TMPRSS2 |
6 | TMPRSS2 ERG FUSION | 381301 | 1% | 89% | 17 | Search TMPRSS2+ERG+FUSION | Search TMPRSS2+ERG+FUSION |
7 | ERG REARRANGEMENT | 325890 | 1% | 100% | 13 | Search ERG+REARRANGEMENT | Search ERG+REARRANGEMENT |
8 | PROSTATE CANCER GENE 3 | 302610 | 1% | 93% | 13 | Search PROSTATE+CANCER+GENE+3 | Search PROSTATE+CANCER+GENE+3 |
9 | PROSTATE CANCER ANTIGEN 3 HUMAN | 277680 | 1% | 92% | 12 | Search PROSTATE+CANCER+ANTIGEN+3+HUMAN | Search PROSTATE+CANCER+ANTIGEN+3+HUMAN |
10 | PROSTATE CANCER | 242631 | 42% | 2% | 508 | Search PROSTATE+CANCER | Search PROSTATE+CANCER |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | XU, B , CHEVARIE-DAVIS, M , CHEVALIER, S , SCARLATA, E , ZEIZAFOUN, N , DRAGOMIR, A , TANGUAY, S , KASSOUF, W , APRIKIAN, A , BRIMO, F , (2014) THE PROGNOSTIC ROLE OF ERG IMMUNOPOSITIVITY IN PROSTATIC ACINAR ADENOCARCINOMA: A STUDY INCLUDING 454 CASES AND REVIEW OF THE LITERATURE.HUMAN PATHOLOGY. VOL. 45. ISSUE 3. P. 488-497 | 79 | 99% | 11 |
2 | PETTERSSON, A , GRAFF, RE , BAUER, SR , PITT, MJ , LIS, RT , STACK, EC , MARTIN, NE , KUNZ, L , PENNEY, KL , LIGON, AH , ET AL (2012) THE TMPRSS2:ERG REARRANGEMENT, ERG EXPRESSION, AND PROSTATE CANCER OUTCOMES: A COHORT STUDY AND META-ANALYSIS.CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION. VOL. 21. ISSUE 9. P. 1497 -1509 | 65 | 84% | 81 |
3 | BURDOVA, A , BOUCHAL, J , TAVANDZIS, S , KOLAR, Z , (2014) TMPRSS2-ERG GENE FUSION IN PROSTATE CANCER.BIOMEDICAL PAPERS-OLOMOUC. VOL. 158. ISSUE 4. P. 502 -510 | 80 | 83% | 5 |
4 | BOSTROM, PJ , BJARTELL, AS , CATTO, JWF , EGGENER, SE , LILJA, H , LOEB, S , SCHALKEN, J , SCHLOMM, T , COOPERBERG, MR , (2015) GENOMIC PREDICTORS OF OUTCOME IN PROSTATE CANCER.EUROPEAN UROLOGY. VOL. 68. ISSUE 6. P. 1033 -1044 | 67 | 71% | 26 |
5 | LIU, WN , (2016) DNA ALTERATIONS IN THE TUMOR GENOME AND THEIR ASSOCIATIONS WITH CLINICAL OUTCOME IN PROSTATE CANCER.ASIAN JOURNAL OF ANDROLOGY. VOL. 18. ISSUE 4. P. 533 -542 | 96 | 59% | 2 |
6 | ABOU-OUF, H , ZHAO, LN , BISMAR, TA , (2016) ERG EXPRESSION IN PROSTATE CANCER: BIOLOGICAL RELEVANCE AND CLINICAL IMPLICATION.JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. VOL. 142. ISSUE 8. P. 1781 -1793 | 81 | 70% | 0 |
7 | FONT-TELLO, A , JUANPERE, N , DE MUGA, S , LORENZO, M , LORENTE, JA , FUMADO, L , SERRANO, L , SERRANO, S , LLORETA, J , HERNANDEZ, S , (2015) ASSOCIATION OF ERG AND TMPRSS2-ERG WITH GRADE, STAGE, AND PROGNOSIS OF PROSTATE CANCER IS DEPENDENT ON THEIR EXPRESSION LEVELS.PROSTATE. VOL. 75. ISSUE 11. P. 1216 -1226 | 48 | 96% | 12 |
8 | FALZARANO, SM , MAGI-GALLUZZI, C , (2013) ERG PROTEIN EXPRESSION AS A BIOMARKER OF PROSTATE CANCER.BIOMARKERS IN MEDICINE. VOL. 7. ISSUE 6. P. 851-865 | 69 | 80% | 8 |
9 | VLAEMINCK-GUILLEM, V , (2014) URINARY PCA3 TEST: WHICH PERSPECTIVES?.MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE. VOL. 38. ISSUE 1. P. 21-30 | 67 | 85% | 0 |
10 | ACS, B , SZARVAS, T , SZEKELY, N , NYIRADY, P , SZASZ, AM , (2015) CURRENT STATE OF ERG AS BIOMARKER IN PROSTATIC ADENOCARCINOMA.CURRENT CANCER DRUG TARGETS. VOL. 15. ISSUE 8. P. 643 -651 | 81 | 66% | 0 |
Classes with closest relation at Level 1 |